Albinterferon alfa-2b. Immunomodulator treatment of hepatitis C virus

Drugs of the Future

Volumn 32, Issue 11, 2007, Pages 937-942

  Sorbera, L A ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA 2B; ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; BELEROFON; HCV INTERFERON ENHANCING THERAPY; HUMAN LEUCOCYTE INTERFERON ALFA; INTERFERON; INTERFERON ALPHA 2B XL; INTERFERON ALPHA 8; NATURAL HUMAN MULTISUBTYPE INTERFERON ALPHA; OMEGA INTERFERON; PEG INTERFERON LAMBDA; PEGINTERFERON; R 7025; RIBAVIRIN; UNCLASSIFIED DRUG;

ABUMIN FUSION TECHNOLOGY; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TECHNOLOGY; VIRUS INFECTION;

EID: 38649142444     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.11.1149301     Document Type: Article

References (30)

1. Prous Science Disease Briefings: Hepatitis C (online publication). Updated 2007.
2. Shepard, C.W. et al. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9): 558-67.
3. Flamm, S.L. Chronic hepatitis C virus infection. JAMA - J Am Med Assoc 2003, 289(18): 2413-7.
4. Spiegel, B.M., Younossi, Z.M., Hays, R.D, Revicki, D., Robbins, S., Kanwal, F. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005, 41(4): 790-800.
5. Hu, K.Q., Vierling, J.M., Redeker, A.G. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001, 8(1): 1-18.
6. Reddy, K.R. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (50 kD). Semin Liver Dis 2004, 24(Suppl. 2): 33-8.
7. McHutchison, J.G., Gordon, S.C., Schiff, E.R. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339(21): 1485-92.
8. Poynard, T., Marcellin, P., Lee, S.S. et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352(9138): 1426-32.
9. Fried, M.W., Shiffman, M.L., Reddy, K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13): 975-82.
10. Manns, M.P., McHutchison, J.G., Gordon, S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001, 358(9286): 958-65.
11. McHutchison, J.G., Manns, M., Patel, K. et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123: 1061-9.
12. Osborn, B.L., Olsen, H.S., Nardelli, B. et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002, 303(2): 540-8.
13. Sung, C., Nardelli, B., Lafleur, D.W. et al. An IFN-β-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res 2003, 23(1): 25-36.
14. Liu, C., Zhu, H., Eylar, J. et al. Albuferon exhibits efficient anti-HCV activity in cell culture. Dig Dis Week (May 14-19, Chicago) 2005, Abst S920.
15. Moore, P., Sidwell, R., Paragas, J., Osborn, B., Nardelli, B., Freimuth, W., Subramanian, M. Albuferon - A novel therapeutic agent with potent in vitro activity against RNA viral agents of bioterrorism. 2nd Annu ASM Biodefense Emerging Dis Res Meet (March 7-10, Baltimore) 2004, Abst 171(G).
16. Moore, P., Paragas, J., Hogan, R. et al. Albuferon beta shows potent in vitro activity against Ebola and the SARS virus. 2nd Annu ASM Biodefense Emerging Dis Res Meet (March 7-10, Baltimore) 2004, Abst 172(G).
17. 125I-HSA-IFNα-2b and in vivo evaluation in rats. Acta Pharmacol Sin [15th World Congr Pharmacol (July 2-7, Beijing) 2006] 2006, 27(Suppl. 1): Abst PI70102.
18. Balan, V., Nelson, D.R., Sulkowski, M.S. et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antiviral Ther 2006, 11(1): 35-45.
19. Bain, V.G., Kaita, K.D., Yoshida, E.M. et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatology 2006, 44(4): 671-8.
20. Fiscella, M., Balan, V., Nelson, D. et al. Favorable pharmacokinetics of albumin interferon alfa-2b in subjects with chronic hepatitis C. 57th Annu Meet Am Assoc Study Liver Dis (AASLD) (Oct 27-31, Boston) 2006, Abst 1140.
21. Moore, P., Balan, V., Nelson, D. et al. Modulation of interferon specific gene expression by Albuferon(TM) in subjects with chronic hepatitis C and correlation with anti-viral response. 40th Annu Meet Eur Assoc Study Liver (EASL) (April 13-17, Paris) 2005, Abst 447.
22. Bain, V.G., Marotta, P., Kaita, K. et al. Comparable antiviral response rates with albumin interferon alfa-2b doses at q2w or q4w intervals in naive subjects with genotype 2 or 3 chronic hepatitis C. J Heptol [42nd Annu Meet Eur Assoc Study Liver (EASL) (April 11-15, Barcelona) 2007] 2007, 46(Suppl. 1): Abst 9.
23. Rustgi, V., Nelson, D., Balan, V. et al. A phase 2 dose-escalation study of albuferon combined with ribavirin in nonresponders to prior interferon based therapy for chronic hepatitis C infection. 41st Annu Meet Eur Assoc Study Liver (EASL) (April 26-30, Vienna) 2006, Abst 113.
24. Neumann, A.U., Rozenberg, L., Zeuzem, S. et al. Albumin interferon alfa-2b dosed at q2w or q4w interval demonstrates comparable week 12 efficacy response in IFN naive, genotype-1 rapid viral responders. J Hepatol [42nd Annu Meet Eur Assoc Study Liver (EASL) (April 11-15, Barcelona) 2007] 2007, 46(Suppl. 1): Abst 624.
25. Zeuzem, S., Benhamou, Y., Bain, V. et al. Antiviral response at week 12 following completion of treatment with albinterferon alpha-2b plus ribavirin in genotype 1, IFN-naive, chronic hepatitis C patients. J Hepatol [42nd Annu Meet Eur Assoc Study Liver (EASL) (April 11-15, Barcelona) 2007], 2007, Abst 779.
26. Zeuzem, S., Benhamou, Y., Shouval, D. et al. Interim (week 12) phase 2B virological efficacy and safety results of albumin interferon alfa-2b combined with ribavirin in genotype 1 chronic hepatitis C infection. 41st Annu Meet Eur Assoc Study Liver (EASL) (April 26-30, Vienna) 2006, Abst 733.
27. McHutchison, J., Zeuzem, S., Benhamou, Y. et al. Interim antiviral and safety data with albumin interferon alfa-2b combined with ribavirin in a phase 2b study conducted in a genotype 1, IFN-naive, chronic hepatitis C population. 57th Annu Meet Am Assoc Study Liver Dis (Oct 27-31, Boston) 2006, Abst 1141.
28. Efficacy of albumin interferon alfa-2b with ribavirin compared to Peg-IFN alfa-2a with ribavirin in IFN naive patients (NCT00402428). ClinicalTrials.gov Web site, October 24, 2007.
29. Efficacy of albumin interferon alfa-2b with ribavirin compared to Peg-IFN alfa-2a with ribavirin in IFN naive patients geno2/3 (NCT00411385). ClinicalTrials.gov Web site, October 24, 2007.
30. Open-label nonrandomized trial for safety and tolerability of albuferon 1,800 mcg with ribavirin for HIV/HCV co-infected individuals (NCT00402428). ClinicalTrials.gov Web site, October 24, 2007.